AR and prostate neoplasm: This suggested that CHD1 loss might activate transcriptional programs that relieve prostate tumor cells from their dependence on AR by reprogramming away from their luminal lineage, as we have reported previously in the setting of combined loss of RB1 and TP53 (Ku et al., 2017, Mu et al., 2017).